News
ESALF
29.25
NaN%
--
Alzheimer's Clinical Trial Results, Sadly Running True To Form
Seeking Alpha · 2d ago
Weekly Report: what happened at ESALF last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at ESALF last week (1117-1121)?
Weekly Report · 11/24 10:28
Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1
Seeking Alpha · 11/22 17:57
Weekly Report: what happened at ESALF last week (1110-1114)?
Weekly Report · 11/17 10:28
Weekly Report: what happened at ESALF last week (1103-1107)?
Weekly Report · 11/10 10:25
Eisai reports H2 results
Seeking Alpha · 11/05 07:08
Weekly Report: what happened at ESALF last week (1027-1031)?
Weekly Report · 11/03 10:26
Merck, Eisai combo meets key goal in advanced kidney cancer trial
Seeking Alpha · 10/28 10:57
Eisai’s MORAb-202 Trial: A Promising Step in Cancer Treatment
TipRanks · 10/27 23:33
Eisai Co.’s Promising Study on E7386: A Game Changer in Cancer Treatment?
TipRanks · 10/27 22:52
Eisai’s Pediatric Epilepsy Study: A Potential Game-Changer for Investors
TipRanks · 10/27 22:26
Eisai Co.’s E1018 Study: A Potential Game-Changer in Malaria Treatment
TipRanks · 10/27 21:11
Eisai’s Tasfygo Study: A Closer Look at Safety in Biliary Tract Cancer
TipRanks · 10/27 20:19
Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study
TipRanks · 10/27 18:44
Eisai Co.’s Tasurgratinib Study: Key Insights for Investors
TipRanks · 10/27 18:06
Eisai’s Lecanemab Study: A Closer Look at Alzheimer’s Treatment Safety
TipRanks · 10/27 17:19
Eisai’s Tazemetostat Study: A Key Update for Investors
TipRanks · 10/27 16:58
Weekly Report: what happened at ESALF last week (1020-1024)?
Weekly Report · 10/27 10:29
Drug launch prices rise significantly outpacing inflation and GDP growth: ICER
Seeking Alpha · 10/23 16:19
More
Webull provides a variety of real-time ESALF stock news. You can receive the latest news about Eisai Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ESALF
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.